Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Roche, who has made a name for himself with his work on iconic religious sites like Chartres cathedral in recent years, is ...

Roche (RHHBY) announced that the Food and Drug Administration has approved Susvimo 100 mg/mL for the treatment of diabetic macular edema, a ...

The duties will also cause self-inflicted economic damage and drive up inflation, warns Quantum Strategy's David Roche.

An ongoing show at MAP, Bengaluru, highlights the transcultural exchange of ideas that resulted in the architectural ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Twenty-four-year-old Caitlyn Micholson is fighting cancer and for a chance to access lifesaving alternative treatment that is ...

The U.S.'s drug regulator has approved Roche's Susvimo drug for the treatment of diabetic macular edema, the leading cause of diabetes-related blindness, the pharmaceutical company said.

The wind farm is projected to have a 30-year lifespan. Roche said the company doesn’t intend to sell, and will be with the ...

Experts at the 2025 Clinical Trial Supply Europe conference will explore supply chain challenges and the impact of AI on ...

The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...